Stephen Biggar
Chairman chez ACADIA PHARMACEUTICALS INC.
Fortune : - $ au 31/03/2024
Profil
Le Dr Stephen R. Biggar est un directeur indépendant de TScan Therapeutics, Inc. et de Kiniksa Pharmaceuticals Ltd. et un président d'ACADIA Pharmaceuticals, Inc. Il siège aux conseils d'administration de TScan Therapeutics, Inc. et de Kiniksa Pharmaceuticals Ltd. et de Vivelix Pharmaceuticals, Ltd. Le Dr Biggar était auparavant employé en tant que directeur indépendant par Synageva BioPharma Corp. et partenaire de Baker Bros. Advisors LP. Il a également siégé au conseil d'administration de BioCryst Pharmaceuticals, Inc. et de Synageva BioPharma Corp. /Old/. Il a obtenu son diplôme de premier cycle à l'Université de Rochester, un diplôme d'études supérieures à l'Université de Stanford et un doctorat à l'Université de Stanford.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
| 24/05/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Stephen Biggar
| Sociétés | Poste | Début |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Chairman | 10/06/2016 |
| KINIKSA PHARMACEUTICALS, LTD. | Director/Board Member | 01/10/2015 |
| TSCAN THERAPEUTICS, INC. | Director/Board Member | 01/03/2021 |
Notch Therapeutics, Inc.
 Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Director/Board Member | - |
Anciens postes connus de Stephen Biggar
| Sociétés | Poste | Fin |
|---|---|---|
| SYNAGEVA BIOPHARMA CORP | Director/Board Member | 22/06/2015 |
Synageva BioPharma Corp. /Old/
 Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Director/Board Member | 04/11/2011 |
| BIOCRYST PHARMACEUTICALS, INC. | Director/Board Member | 10/10/2011 |
Vivelix Pharmaceuticals, Ltd.
 Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Director/Board Member | - |
Baker Bros. Advisors LP
 Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Portfolio Manager-Equities | - |
Formation de Stephen Biggar
| Rochester Christian University | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Baker Bros. Advisors LP
Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Finance |
Synageva BioPharma Corp. /Old/
Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Vivelix Pharmaceuticals, Ltd.
Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Health Technology |
Notch Therapeutics, Inc.
Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Health Technology |
